NASDAQ:SVRA Savara Q1 2025 Earnings Results & Report $4.76 -0.02 (-0.42%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$5.00 +0.24 (+5.00%) As of 06:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Savara missed analyst earnings expectations in its Q1 2025 results, released August 13, 2025. The company reported EPS of -$0.14 versus the -$0.12 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateAugust 13, 2025TimeBefore Market Opens Savara EPS ResultsActual EPS-$0.14Consensus EPS -$0.12Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate0 of last 8 quartersSavara Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsSavara's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Savara Q1 2025 Earnings FAQ Did Savara beat earnings estimates for Q1 2025? Savara (NASDAQ:SVRA) reported earnings of -$0.14 per share for Q1 2025, missing the consensus estimate of -$0.12. The report was announced on Wednesday, August 13, 2025. When is Savara's next earnings date? Savara's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Savara on the company's earnings history page. Savara Earnings HeadlinesWill Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?October 13 at 12:08 PM | finance.yahoo.comSavara Inc. (SVRA) - What Are Analysts Thinking About This Stock?October 13 at 4:15 AM | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026October 12 at 4:05 PM | businesswire.comSavara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.October 8, 2026 | americanbankingnews.comJPMorgan Initiates Savara at Overweight With $12 Price TargetOctober 7, 2026 | marketscreener.comMSee More Savara Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email. Email Address About SavaraSavara (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing. Savara has conducted clinical development activities in the United States and internationally, including Europe. The company’s research and development strategy is centered on advancing therapies for serious pulmonary conditions with limited treatment options. Molgramostim is an investigational product and its availability and regulatory status may vary by jurisdiction. Savara is headquartered in Austin, Texas, and is led by Chief Executive Officer Matthew Pauls. The company’s history includes a focus on rare respiratory diseases and the development of inhaled therapies intended to address underlying disease mechanisms rather than solely manage symptoms.View Savara ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
